1
|
Rust R, Weber RZ, Grönnert L, Mulders G, Maurer MA, Hofer AS, Sartori AM, Schwab ME. Anti-Nogo-A antibodies prevent vascular leakage and act as pro-angiogenic factors following stroke. Sci Rep 2019; 9:20040. [PMID: 31882970 PMCID: PMC6934709 DOI: 10.1038/s41598-019-56634-1] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 12/16/2019] [Indexed: 12/31/2022] Open
Abstract
Angiogenesis is a key restorative process following stroke but has also been linked to increased vascular permeability and blood brain barrier (BBB) disruption. Previous pre-clinical approaches primarily focused on the administration of vascular endothelial growth factor (VEGF) to promote vascular repair after stroke. Although shown to improve angiogenesis and functional recovery from stroke, VEGF increased the risk of blood brain barrier disruption and bleedings to such an extent that its clinical use is contraindicated. As an alternative strategy, antibodies against the neurite growth inhibitory factor Nogo-A have recently been shown to enhance vascular regeneration in the ischemic central nervous system (CNS); however, their effect on vascular permeability is unknown. Here, we demonstrate that antibody-mediated Nogo-A neutralization following stroke has strong pro-angiogenic effects but does not increase vascular permeability as opposed to VEGF. Moreover, VEGF-induced vascular permeability was partially prevented when VEGF was co-administered with anti-Nogo-A antibodies. This study may provide a novel therapeutic strategy for vascular repair and maturation in the ischemic brain.
Collapse
Affiliation(s)
- Ruslan Rust
- Institute for Regenerative Medicine, University of Zurich, 8952, Schlieren, Zurich, Switzerland. .,Dept. of Health Sciences and Technology, ETH Zurich, 8092, Zurich, Switzerland.
| | | | - Lisa Grönnert
- Institute for Regenerative Medicine, University of Zurich, 8952, Schlieren, Zurich, Switzerland
| | - Geertje Mulders
- Dept. of Health Sciences and Technology, ETH Zurich, 8092, Zurich, Switzerland
| | - Michael A Maurer
- Institute for Regenerative Medicine, University of Zurich, 8952, Schlieren, Zurich, Switzerland
| | - Anna-Sophie Hofer
- Institute for Regenerative Medicine, University of Zurich, 8952, Schlieren, Zurich, Switzerland.,Dept. of Health Sciences and Technology, ETH Zurich, 8092, Zurich, Switzerland
| | - Andrea M Sartori
- Institute for Regenerative Medicine, University of Zurich, 8952, Schlieren, Zurich, Switzerland.,Dept. of Health Sciences and Technology, ETH Zurich, 8092, Zurich, Switzerland
| | - Martin E Schwab
- Institute for Regenerative Medicine, University of Zurich, 8952, Schlieren, Zurich, Switzerland.,Dept. of Health Sciences and Technology, ETH Zurich, 8092, Zurich, Switzerland
| |
Collapse
|
2
|
Vascular Endothelial Growth Factor is Increased in Aqueous Humor of Acute Primary Angle-Closure Eyes. J Glaucoma 2017; 25:e647-51. [PMID: 25719239 DOI: 10.1097/ijg.0000000000000242] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE To measure and compare the levels of vascular endothelial growth factor (VEGF) in the aqueous humor of patients with acute primary angle closure (APAC), primary angle-closure glaucoma (PACG), and normal cataract (controls). METHODS Aqueous humor samples were prospectively collected from 38 APAC eyes, 36 PACG eyes, and 25 nonglaucomatous cataract control eyes. The levels of aqueous humor VEGF were measured using enzyme-linked immunoassays. The clinical characteristics of participants were also collected for correlation analysis. RESULTS VEGF was detected in aqueous humor samples of 35 of 38 APAC patients (mean±SE of the mean, 935±258 pg/mL), 30 of 36 PACG patients (165±37.5 pg/mL), and 16 of 25 cataract controls (69.5±13.5 pg/mL). The mean concentration of VEGF in APAC eyes was 13.5 and 5.7 times higher than that in controls and PACG eyes, respectively, and these differences were statistically significant (both P<0.0167). In the correlation analysis that included all participants, the aqueous humor VEGF level was found to correlate negatively with axial length (ρ=-0.342, P=0.001), and positively with intraocular pressure (ρ=0.434, P<0.001). CONCLUSIONS VEGF was significantly increased in aqueous humor of APAC eyes. An increase in aqueous humor VEGF may be the result of the characteristic ocular ischemia and hypoxia observed in APAC eyes as a consequence of sudden excessive increases in intraocular pressure during the acute episode.
Collapse
|
3
|
Parris GE. A Hypothesis Concerning the Biphasic Dose-response of Tumors to Angiostatin and Endostatin. Dose Response 2015; 13:10.2203_dose-response.14-020.Parris. [PMID: 26675544 PMCID: PMC4674172 DOI: 10.2203/dose-response.14-020.parris] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
This manuscript proposes a hypothesis to explain the U-shaped dose-response observed for angiostatin and other high-molecular-weight drugs in various anti-cancer bio-assays. The dose-response curves for angiostatin and endostatin (measured as suppression of tumor growth) go through an optimum (i.e., minimum tumor growth) and then becomes less effective at higher doses. The literature suggests that at lower doses the primary action of these high-molecular-weight drugs is to counteract the angiogenic effects of vascular endothelial growth factor (VEGF). To do this, the drugs must pass out of the blood vessel and enter the extra-cellular matrix (ECM) where VEGF induces the growth and fusion of tip cells. Ironically, VEGF actually facilitates access of the drugs to the ECM by making the vascular endothelium leaky. At higher doses, the high-molecular-weight drugs seem to reverse VEGF-induced permeability of the endothelium. Thus, at high dose rates, it is hypothesized that the drugs are not able to enter the ECM and block the angiogenic effects of VEGF there. As a result, high doses of the drugs do not suppress vascularization of the tumor or tumor growth. Moreover, if the permeability of the vessels is suppressed, the VEGF released by the stroma is concentrated in the ECM where it amplifies the angiogenic activity around the tumor.
Collapse
Affiliation(s)
- George E Parris
- Montgomery College, Department of Chemistry, Rockville, MD, USA
| |
Collapse
|
4
|
Guzmán-Pérez CA, Ibarra-Sánchez A, Ventura-Gallegos JL, González-Espinosa C, García-Román J, Zentella-Dehesa A. An in vivo model to study the effects of tumoral soluble factors on the vascular permeability in mice. Methods Mol Biol 2014; 1165:187-95. [PMID: 24839026 DOI: 10.1007/978-1-4939-0856-1_13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Some cancer cell lines release soluble factors that activate the endothelial cells in vitro; also endothelial activation in vivo includes an increased expression of adhesion molecules on the apical membrane, and an increased permeability, which may contribute to the extravasation process of circulating cells. We have adapted the Miles assay into a protocol that uses IgE/antigen complex and VEGF-1 as controls. The Miles assay comprises the intradermic injection of a pro-inflammatory agent into the skin and the intravenous introduction of a dye; the increase in vascular permeability will allow for the extravasation of the dye and thus the skin will be stained. The dye is then extracted from the dissected skin and quantified by spectrophotometry. The use of localized treatments will allow for testing a larger number of experimental samples in the same animal. With this model, the effects of tumoral soluble factors (TSFs) on endothelial permeability can be studied, as well as the signaling pathways involved. It can also serve to study the interactions between endothelial, immune, and cancer cells during the extravasation process.
Collapse
Affiliation(s)
- César Alejandro Guzmán-Pérez
- Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, UNAM, Apartado postal 70228, Coyoacán, CP 04510, México, DF, México,
| | | | | | | | | | | |
Collapse
|
5
|
Nensa F, Stattaus J, Morgan B, Horsfield MA, Soria JC, Besse B, Gounant V, Khalil A, Seng K, Fischer B, Krissel H, Laurent D, Christoph D, Eberhardt WEE, Gauler TC. Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer. Future Oncol 2014; 10:823-33. [PMID: 24799063 DOI: 10.2217/fon.13.248] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
ABSTRACT: Aims: To assess the utility of dynamic contrast-enhanced MRI parameters in the demonstration of early antiangiogenic effects and as prognostic biomarkers in second-line treatment of advanced-stage non-small-cell lung cancer with vatalanib. Patients & methods: The transfer constant (Ktrans) and the initial area under the contrast concentration–time curve at 60 s (AUC60) were assessed in 46 patients. Changes were compared with response evaluation from computed tomography imaging and Response Evaluation Criteria In Solid Tumors guidelines. Results: Statistically significant mean reductions in Ktrans (38.4%; p < 0.0001) and AUC60 (24.9%; p < 0.0001) were found at day 2. After 12 weeks, 16 patients (35%) demonstrated stable disease and 30 (65%) demonstrated progressive disease. No statistically significant differences in day 2 Ktrans and AUC60 reductions between stable disease and progressive disease patients were found. Conclusion: Dynamic contrast-enhanced MRI can demonstrate a statistically significant reduction in vascular parameters of non-small-cell lung cancer, but does not predict patient outcome.
Collapse
Affiliation(s)
- Felix Nensa
- Department of Diagnostic & Interventional Radiology & Neuroradiology, University Hospital of University Duisburg-Essen, Essen, Germany
| | - Jörg Stattaus
- Department of Radiology & Nuclear Medicine, Bergmannsheil und KinderklinikBuer GmbH, Gelsenkirchen, Germany
| | - Bruno Morgan
- Department of Cancer Studies & Molecular Medicine, University of Leicester, Leicester Royal Infirmary, Infirmary Square, Leicester, UK
| | - Mark A Horsfield
- Department of Cardiovascular Sciences, University of Leicester, Leicester Royal Infirmary, Infirmary Square, Leicester, UK
| | | | - Benjamin Besse
- Département de Médecine, Institut Gustave Roussy, Villejuif, France
| | - Valerie Gounant
- Unité Fonctionnelle de Pneumologie (Orientation Oncologique), Hôpital Tenon, Paris, France
| | - Antoine Khalil
- Unité Fonctionnelle de Pneumologie (Orientation Oncologique), Hôpital Tenon, Paris, France
| | - Katja Seng
- Department of Diagnostic & Interventional Radiology & Neuroradiology, University Hospital of University Duisburg-Essen, Essen, Germany
| | - Berthold Fischer
- Department of Respiratory Diseases III, Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - Heiko Krissel
- Global Clinical Development Oncology, Bayer Pharma AG, Berlin, Germany
| | - Dirk Laurent
- Global Clinical Development Oncology, Bayer Pharma AG, Berlin, Germany
| | - Daniel Christoph
- Department of Medicine (Cancer Research), West German Tumor Center, University Hospital of University Duisburg-Essen, Essen, Germany
- Department of Medicine, Division of Medical Oncology, University of Colorado Denver, Aurora, CO, USA
| | - Wilfried EE Eberhardt
- Department of Medicine (Cancer Research), West German Tumor Center, University Hospital of University Duisburg-Essen, Essen, Germany
| | - Thomas C Gauler
- Department of Medicine (Cancer Research), West German Tumor Center, University Hospital of University Duisburg-Essen, Essen, Germany
| |
Collapse
|
6
|
Zhang A, Liang L, Niu H, Xu P, Hao Y. Protective effects of VEGF treatment on focal cerebral ischemia in rats. Mol Med Rep 2012; 6:1315-8. [PMID: 22965224 DOI: 10.3892/mmr.2012.1069] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2012] [Accepted: 07/25/2012] [Indexed: 11/06/2022] Open
Abstract
The aim of this study was to determine the effects of VEGF treatment on focal cerebral ischemia in rats. Rats were administered PBS or VEGF at concentrations of 10, 20 or 30 µg/ml. The effects of VEGF on the rat infarct volume and neurological deficits were investigated. Transmission electron microscopy was used to observe the ultrastructure of the cerebral cortex. Treatments with VEGF reduced the infarct volume and improved neurological functions. VEGF increased microvessel generation and also inhibited apoptosis in the cerebral cortex and basal ganglia. For the rats in the 30 µg/ml VEGF group, an even higher number of proliferative endothelial cells were observed by electron microscopy. In conclusion, VEGF treatment has protective effects on focal cerebral ischemia in rats.
Collapse
Affiliation(s)
- Aimei Zhang
- The Affiliated Hospital of Jining Medical College, Jining, Shandong 272029, P.R. China
| | | | | | | | | |
Collapse
|